2-羟基-4-噻吩-2-基苯甲酸 | 1261968-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-4-噻吩-2-基苯甲酸
• 英文名称: 2-hydroxy-4-(thien-2-yl)benzoic acid
• 英文别名: 2-hydroxy-4-(2-thienyl)benzoic acid；2-Hydroxy-4-(thiophen-2-YL)benzoic acid；2-hydroxy-4-thiophen-2-ylbenzoic acid
• CAS: 1261968-90-4
• 化学式: C₁₁H₈O₃S
• 分子量: 220.249
• InChiKey: KJPVYHFBHZUOOV-UHFFFAOYSA-N

物化性质

• 沸点：
  416.0±45.0 °C(Predicted)
• 密度：
  1.419±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl 2-methoxy-4-(thiophen-2-yl)benzoate 在 水 、 三氯化硼 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-羟基-4-噻吩-2-基苯甲酸
  参考文献：
  名称：

  Synthesis and biological evaluation of salicylate-based compounds as a novel class of methionine aminopeptidase inhibitors

  摘要：

  A series of salicylate-based compounds were designed and synthesized based on the simple function group replacement from our previously reported catechol-containing inhibitors of methionine aminopeptidase (MetAP). Some of these salicylate derivatives showed similar potency and metalloform selectivity, and some showed considerable antibacterial activity. These findings are consistent with our previous conclusion that Fe(II) is the likely metal used by MetAP in bacterial cells and provide new lead structures that can be further developed as novel antibacterial agents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.080

文献信息

• Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1
  作者：María Dolores Moya-Garzón、Cristina Martín Higueras、Pablo Peñalver、Manuela Romera、Miguel X. Fernandes、Francisco Franco-Montalbán、José A. Gómez-Vidal、Eduardo Salido、Mónica Díaz-Gavilán

  DOI：10.1021/acs.jmedchem.8b00399

  日期：2018.8.23

  oxidase (GO) inhibition is still to be verified, most of the salicylic acids described here are GO inhibitors with IC50 values down to 3 μM. Binding mode of salicylic acids inside GO has been studied using in silico methods, and preliminary structure–activity relationships have been established. The drug-like structure and ease of synthesis of our compounds make them promising hits for structural optimization

  原发性高草酸尿症1型（PH1）是一种与乙醛酸代谢有关的罕见的威胁生命的遗传疾病，其特征是草酸钙晶体的积累。当前的治疗涉及肝和/或肾移植，这些过程具有显着的发病率和死亡率，并且需要长期的免疫抑制。因此，迫切需要药物治疗。我们在这里介绍水杨酸衍生物的空前活性，它是能够在低微摩尔范围内降低高草酰脲肝细胞中草酸盐输出的试剂，这意味着其在治疗PH1中的潜在用途。尽管这种表型活性与乙醇酸氧化酶（GO）抑制的相关性尚待验证，但此处描述的大多数水杨酸都是具有IC 50的GO抑制剂值低至3μM。水杨酸在GO内部的结合模式已通过计算机方法进行了研究，并建立了初步的结构-活性关系。类化合物的药物结构和易合成性使其成为结构优化的有前途的命中方法。
• EP3593803
  申请人：——

  公开号：——

  公开（公告）日：——
• COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION
  申请人：UNIVERSIDAD DE GRANADA

  公开号：US20200197418A1

  公开（公告）日：2020-06-25

  The present invention relates to the use of derivatives of salicylic acid for the treatment of diseases or conditions linked to GO and/or PRODH2 enzyme activity, in particular diseases linked to an excess of oxalate, and for the treatment of patients with renal insufficiency (uremia or azotaemia) receiving haemodialysis or peritoneal dialysis, in particular patients treated with ascorbic acid (vitamin C), which is metabolised to oxalate, or patients with fibromyalgia and vulvar pain.